|
Did you know . . .
- You now bear more
responsibility than ever in picking a drug name?
- The FDA now has new
requirements for naming your new product?
- You must be in compliance with the USPTO, FDA, and the
Lanham Act?
Register now to get expert insight into
navigating these new requirements from Lisa Tittemore and
Keith Toms, partners at Bromberg & Sunstein LLP.
Dan Pomroy, Thomson CompuMark’s pharmaceutical account manager,
will moderate the discussion, which will focus on issues
unique to the prosecution and enforcement of pharmaceutical
trademarks. Our program will cover:
- The key differences between
the FDA and USPTO approaches to approving pharmaceutical
trademarks
- The implications each
approach has on selecting, registering, and using
pharmaceutical trademarks
- The impact that the FDA's recently proposed drug-name
pilot program may have on the drug naming process
We look forward to hosting you on November 5.
| 
